INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///
February 16 — 18, 2023 San Francisco, CA

Level 1, West Hall
5 Poster Presentations

ASCO® GU Symposium 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare.

We are pleased to share our latest scientific and clinical research findings during the ASCO Genitourinary Cancers Symposium 2023.

Schedule a meeting with us
Poster Presentations
February 16, 2023
Times
11:30am - 1:00pm PST;
5:45pm - 6:45pm PST

Presentation Number: Poster J14
Authors
Elisa Ledet (Tulane University), Elizabeth Mauer (Tempus), Oliver Sartor (Tulane University), et al.

Pathogenic BRAF K601E Mutations in Prostate Cancer: Frequency and Distribution

BRAF mutations are known to be clinically significant in a variety of cancers. While the prevalence of BRAF p.V600E is well described, the remaining landscape of pathogenic/likely pathogenic (P/LP) BRAF mutations is poorly understood. This study leveraged Tempus’ multimodal dataset to evaluate the prevalence of BRAF P/LP variants in a large-scale cohort of prostate cancer patients.

Times
11:30am - 1:00pm PST;
5:45pm - 6:45pm PST

Presentation Number: Poster J17
Authors
John Shen (UCLA), Liang Wang (UCLA), Ali Khaki (Stanford), Rafael E. Jimenez (Mayo Clinic), Elizabeth Mauer (Tempus), Manish Kohli (University of Utah), et al.

Homologous Recombination Repair (HRR) Mutation Concordance Between Liquid Biopsy (LB) and Tumor Tissue by NGS in a Real-World Prostate Cancer (PC) Database

Utilization of NGS to identify HRR mutations is indicated in advanced prostate cancer. This study used Tempus’ large real-world multimodal database to determine concordance between plasma ctDNA and primary tumor tissue and/or metastatic tissue for BRCA1, BRCA2, and ATM mutations in prostate cancer patients. In addition, these data were used to establish the utility of combined liquid biopsy and tissue testing in this setting.

Times
11:30am - 1:00pm PST;
5:45pm - 6:45pm PST

Presentation Number: Poster B1
Authors
Oliver Sartor (Tulane University), Elisa Ledet (Tulane University), Nicholas Mitsiades (UC Davis), Ellen Jaeger (Tempus)

CDK12 Pathogenic Mutations in African American and White Patients with Prostate Cancer

African American men are underrepresented in prostate cancer trials despite having a greater probability of both developing and dying from prostate cancer. CDK12 mutations in prostate cancer are associated with aggressive disease, increased metastasis, and decreased overall survival. Preliminary data suggests pathogenic CDK12 mutations may be more common in African American men. This study reports real-world NGS data from Tempus’ multimodal database to investigate the frequency of pathogenic CDK12 mutations in African American and White prostate cancer patients.

February 17, 2023
Times
12:30pm PST

Presentation Number: Poster H9
Authors
Mairead Kearney (Merck), Chiemeka Ike (EMD Serono), Ambar Modh (Tempus), Ken Carson (Rush), et al.

Real-World Treatment Patterns and Sequencing in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (LA/MUC) in the US

The 2020 FDA approval of avelumab in locally advanced/metastatic urothelial cancer provided new opportunities for the sequence of treatment approaches. However, little is known about the changes that have occurred in clinical practice since then. Further, treatment sequencing paradigms for these patients still lacks consensus. This study used Tempus real-world data to describe the characteristics and treatment patterns of patients with locally advanced/metastatic urothelial cancer.

February 18, 2023
Times
7:00am - 8:00am PST;
12:30pm – 2:00pm PST

Presentation Number: Poster K1
Authors
Nataliya Mar (UC Irvine), Arash Rezazadeh (UC Irvine), Arya Ashok (Tempus), Ellen Jaeger (Tempus)

Molecular Characteristics of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Harboring TERT Mutations

There is a large unmet need for identifying prognostic and predictive biomarkers in advanced renal cell carcinoma (RCC) and Urothelial Carcinoma (UC). This study aimed to utilize Tempus’ multimodal database to analyze the molecular and immune biomarker landscape in TERT mutated versus wild type RCC and UC.

Schedule a meeting with us

We'll be in touch shortly.